| Revision as of 09:29, 31 October 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number').← Previous edit |
Latest revision as of 23:37, 3 December 2023 edit undoCitation bot (talk | contribs)Bots5,429,317 edits Add: doi-access. | Use this bot. Report bugs. | #UCB_CommandLine |
| (20 intermediate revisions by 15 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Monoclonal antibody}} |
|
{{Drugbox |
|
{{Drugbox |
|
|
| Verifiedfields = changed |
|
|
| Watchedfields = changed |
|
|
| verifiedrevid = 458268914 |
|
| type = mab |
|
| type = mab |
|
| image = |
|
| image = |
|
| alt = |
|
| alt = |
|
| mab_type = mab |
|
| mab_type = mab |
|
| source = zu |
|
| source = zu/o |
|
| target = ] |
|
| target = ] |
|
<!--Clinical data--> |
|
<!--Clinical data --> |
|
| tradename = |
|
| tradename = |
|
| Drugs.com = |
|
| Drugs.com = |
| Line 13: |
Line 17: |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_category= |
|
| pregnancy_category= |
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> |
|
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> |
|
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> |
| Line 19: |
Line 23: |
|
| legal_status = |
|
| legal_status = |
|
| routes_of_administration = |
|
| routes_of_administration = |
|
⚫ |
<!-- Pharmacokinetic data --> |
|
|
|
| ⚫ |
<!--Pharmacokinetic data--> |
|
|
| bioavailability = |
|
| bioavailability = |
|
| protein_bound = |
|
| protein_bound = |
| Line 26: |
Line 29: |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| excretion = |
|
| excretion = |
|
⚫ |
<!-- Identifiers --> |
|
|
|
|
|
| CAS_number_Ref = {{cascite|changed|??}} |
| ⚫ |
<!--Identifiers--> |
|
|
| CAS_number = <!-- blanked - oldvalue: 1202526-59-7 --> |
|
| CAS_number = 1202526-59-7 |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = QOK1YYH7J2 |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
|
| PubChem = |
|
| PubChem = |
|
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
| DrugBank = |
|
| ChemSpiderID = NA |
|
| KEGG = D10187 |
|
|
| KEGG_Ref = {{keggcite|changed|kegg}} |
|
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
|
| ChemSpiderID = none |
|
⚫ |
<!-- Chemical data --> |
|
|
| C = 6436 | H = 9910 | N = 1710 | O = 2004 | S = 44 |
|
|
| synonyms = MLTA3698A |
|
⚫ |
}} |
|
|
|
|
|
|
'''Pateclizumab''' ('''MLTA3698A''') is an immunomodulator. It binds to ].<ref>{{cite journal | author = ] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 | journal = WHO Drug Information | volume = 25 | issue = 2 | year = 2011 | url =https://www.who.int/medicines/publications/druginformation/innlists/Final_PL105.pdf }}{{dead link|date=December 2021|bot=medic}}{{cbignore|bot=medic}}</ref><ref>, '']''.</ref><ref>{{cite journal |vauthors=Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, Tang MT, Grogan JL, Hsieh F, Davis JC |title=Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study) |journal=Arthritis Res. Ther. |volume=16 |issue=5 |pages=467 |date=October 2014 |pmid=25359150 |pmc=4243296 |doi=10.1186/s13075-014-0467-3 |doi-access=free }}</ref><ref>{{cite journal |vauthors=Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC |title=Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial |journal=Arthritis Res. Ther. |volume=14 |issue=1 |pages=R6 |date=January 2012 |pmid=22225620 |pmc=3392792 |doi=10.1186/ar3554 |doi-access=free }}</ref><ref>{{cite journal |vauthors=Wang H, Schuetz C, Arima A, Chihaya Y, Weinbauer GF, Habermann G, Xiao J, Woods C, Grogan J, Gelzleichter T, Cain G |title=Assessment of placental transfer and the effect on embryo-fetal development of a humanized monoclonal antibody targeting lymphotoxin-alpha in non-human primates |journal=Reprod. Toxicol. |volume=63 |pages=82–95 |date=August 2016 |pmid=27211603 |doi=10.1016/j.reprotox.2016.05.014 |s2cid=41454952 }}</ref><ref>{{cite journal |vauthors=Hirose T, Fukuma Y, Takeshita A, Nishida K |title=The role of lymphotoxin-α in rheumatoid arthritis |journal=Inflamm. Res. |volume=67 |issue=6 |pages=495–501 |date=June 2018 |pmid=29541795 |doi=10.1007/s00011-018-1139-6 |s2cid=3910200 }}</ref> |
| ⚫ |
<!--Chemical data--> |
|
|
| chemical_formula = |
|
|
| molecular_weight = |
|
|
|
|
|
|
|
This drug was developed by ]/]. |
| ⚫ |
}} |
|
|
|
|
|
'''Pateclizumab''' is an immunomodulator. It binds to ].<ref>{{cite journal | author = ] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 | journal = WHO Drug Information | volume = 25 | issue = 2 | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL105.pdf | format=PDF}}</ref> |
|
|
|
|
|
|
== References == |
|
== References == |
|
<references/> |
|
<references/> |
|
|
|
|
|
|
|
|
{{monoclonals for immune system}} |
|
{{Monoclonals for immune system}} |
|
|
{{Chemokine receptor modulators}} |
|
|
|
|
|
] |
|
|
|
|
|
|
|
|